Abiraterone Acetate Tablets

Effects and efficacy:
This product is used in combination with prednisone or prednisolone to treat metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high-risk metastatic endocrine-sensitive prostate cancer (mHSPC), including those who have not received endocrine therapy or have received endocrine therapy for no longer than 3 months.
Usage and dosage:
The recommended dose of this product is 1000mg (4×250mg tablets) orally once a day. This product is used in combination with prednisone or prednisolone 5mg orally twice a day to treat patients with metastatic castration-resistant prostate cancer (mCRPC). This product is used in combination with prednisone or prednisolone 5mg orally once a day to treat newly diagnosed high-risk metastatic endocrine-sensitive prostate cancer (mHSPC). Patients receiving this product should also receive gonadotropin-releasing hormone analogs (GnRHa) or should have undergone bilateral orchiectomy. This product should be taken on an empty stomach at least 1 hour before and at least 2 hours after meals. This product should be swallowed whole with water. Do not break or chew it.
Adverse reactions: This product may cause hypertension, hypokalemia and retention. The most common adverse reactions in clinical practice are peripheral edema, hypokalemia, hypertension and urinary tract infection. Other important adverse reactions include heart disease, liver toxicity, fractures and allergic alveolitis. Usually, the adverse reactions of mineralocorticoids can be effectively controlled after treatment. The combined use of corticosteroids can reduce the incidence and severity of these adverse drug reactions.
Drug contraindications:
Allergic to this product is contraindicated. It is contraindicated during pregnancy and lactation.